



IFW

Patent Application
Attorney Docket No. PC25687A

It is hereby certified that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 30 day of June 2004

By

Irene Grantham
(Signature of person mailing)
Irene Grantham

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Christopher Ian Dallman, et :
al.

APPLICATION NO.: 10/763,794 : Examiner: To Be Assigned

FILING DATE: January 22, 2004 : Group Art Unit: 1615

TITLE: Crystalline Therapeutic Agent :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: June 30, 2004
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4288

Respectfully submitted,

Martha G. Munchhof
Martha G. Munchhof
Attorney for Applicant(s)
Reg. No. 47,811



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25687A				SERIAL NO. 10/763,794								
		APPLICANT Christopher Ian Dallman, et al.												
		FILING DATE January 22, 2004				GROUP 1615								
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	US	6	1	0	6	8	6	4	8/22/00	Dolan, et al.	424	488		
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	9	1	1	1	1	8	8	8/8/91	PCT	A61K	9/00		
	WO	9	4	0	2	5	1	8	2/3/94	PCT	C08B	37/16		
	WO	9	4	2	8	9	0	2	12/22/94	PCT	A61K	31/505		
	WO	9	8	5	5	1	0	8	12/10/98	PCT	A61K	47/48		
	WO	0	1	1	2	4	9	5	7/5/01	PCT	A61K	9/14		
	EP	0	4	6	3	7	5	6	1/2/92	EP	C07D	487/04		
	EP	0	8	1	2	8	4	5	7/14/99	EP	C07D	487/04		
	EP	0	5	5	4	1	4	5	4/19/00	EP	C07D	487/04		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		Stephenson, et al., "Formation of Isomorphic Desolvates: Creating a Molecular Vacuum", <u>J. Pharm. Sci.</u> 87 (5), pp. 536-542 (1998)												
		Finnin, et al., "Transdermal Penetration Enhancers: Applications, Limitations, and Potential", <u>J. Pharm. Sci.</u> 88 (10), pp. 955-958 (1999)												
		Zhu, et al., "Influence of Water Activity in Organic Solvent + Water Mixtures on the Nature of the Crystallizing Drug Phase", <u>International Journal of Pharmaceutics</u> 135 , pp. 151-160 (1996)												
		Liang, et al., "Fast-dissolving Intraoral Drug Delivery Systems", <u>Exp. Opin. Ther. Patents</u> 11 (6), pp. 981-986 (2001)												
		Verma, et al., "Current Status of Drug Delivery Technologies and Future Directions", <u>Pharm. Tech. On-line</u> 25 (2), pp. 1-14 (2001)												
EXAMINER														
DATE CONSIDERED														
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														